<DOC>
	<DOCNO>NCT00413036</DOCNO>
	<brief_summary>Subjects qualify receive oral lenalidomide daily day 1-21 every 28 day cycle . Treatment continue disease progression , unacceptable adverse event develop</brief_summary>
	<brief_title>A Study Revlimid Treatment Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Key Inclusion criterion Biopsy proven aggressive nonhodgkin 's lymphoma Follicular center lymphoma Grade 3 . Diffuse large Bcell lymphoma . Mantle cell lymphoma . Transformed lymphoma . Relapsed refractory previous therapy lymphoma At least one prior combination chemotherapy regime Measurable disease cross sectional imaging least 2 cm long diameter Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 2 Willing follow pregnancy precaution Key Exclusion criterion Any follow laboratory abnormality . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm^3 ( 1.5*10^9/L ) . Platelet count &lt; 60,000/mm^3 ( 60*10^9/L ) . Calculated creatinine clearance &lt; 50mL/min Serum glutamic oxaloacetic transaminase/aspartate aminotransferase ( SGOT/AST ) Serum glutamic pyruvic transaminase/Alanine transaminase ( SGPT/ALT ) 5.0 time upper limit normal ( ULN ) . Serum total bilirubin &gt; 2.0 mg/dL ( 34 Âµmol/L ) /conjugated bilirubin &gt; 0.8mg/dL . Subjects candidate willing undergo autologous stem cell transplant . History active Central Nervous System ( CNS ) lymphoma within previous 6 month History malignancy within past year Positive Human immunodeficiency virus ( HIV ) active Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Celgene</keyword>
	<keyword>Revlimid</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Non-hodgkin 's lymphoma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC5013</keyword>
	<keyword>NHL</keyword>
</DOC>